title: Effect of rosuvastatin therapy on troponin I release following percutaneous coronary intervention in nonemergency patients (from the TIP 3 study).
abstract: Several randomized studies have suggested that pretreatment with statins may reduce a periprocedural biomarker release in patients who underwent percutaneous coronary intervention (PCI); however, results remain controversial. The purpose of this study was to investigate the effect of a 1-day rosuvastatin therapy on troponin I release in patients who underwent nonemergency PCI. A total of 445 patients with angina pectoris were randomly assigned to therapy with rosuvastatin (20 mg 12 hours before coronary angiography + 20 mg immediately before PCI; rosuvastatin group, 220 patients) or PCI without statin therapy (control group, 225 patients). In patients taking statins (73%), rosuvastatin was added to their long-term statin therapy. The primary end point was the incidence of TnI microleak defined as TnI elevation >1.5× upper limit of normal, and the secondary end point was the incidence of post-PCI TnI elevation >3× upper limit of normal. The incidence of primary and secondary end point in the rosuvastatin versus control group was 13.6% versus 12% (p = 0.61) and 8.2% versus 7.1% (p = 0.67), respectively. Patients with C-reactive protein ≥2.0 mg/L had a decreased release of post-PCI TnI in the rosuvastatin group (0.032 [0.010 to 0.143] μg/L vs 0.056 [0.018 to 0.241] μg/L; p = 0.04). In conclusion, 1-day rosuvastatin therapy (20 mg twice a day) did not influence post-PCI TnI release in patients with angina. However, these results suggest that, in patients with an advanced inflammatory status, rosuvastatin loading therapy might have a cardioprotective effect.
authors.affiliation: Department of Cardiology, Second Medical School, Charles University, University Hospital Motol, Prague, Czech Republic. Electronic address: josef.veselka@fnmotol.cz.
authors.forename: Josef
authors.initials: J
authors.lastname: Veselka
authors.affiliation: Department of Cardiology, Second Medical School, Charles University, University Hospital Motol, Prague, Czech Republic.
authors.forename: Petr
authors.initials: P
authors.lastname: Hájek
authors.affiliation: Department of Cardiology, Second Medical School, Charles University, University Hospital Motol, Prague, Czech Republic.
authors.forename: Pavol
authors.initials: P
authors.lastname: Tomašov
authors.affiliation: Department of Cardiology, Second Medical School, Charles University, University Hospital Motol, Prague, Czech Republic.
authors.forename: David
authors.initials: D
authors.lastname: Tesař
authors.affiliation: First Department of Medicine, Charles University in Prague, Medical School and Teaching Hospital in Pilsen, Pilsen, Czech Republic.
authors.forename: Hana
authors.initials: H
authors.lastname: Brůhová
authors.affiliation: First Department of Medicine, Charles University in Prague, Medical School and Teaching Hospital in Pilsen, Pilsen, Czech Republic.
authors.forename: Martin
authors.initials: M
authors.lastname: Matějovič
authors.affiliation: Department of Cardiology, Podlesi Hospital, Trinec, Czech Republic.
authors.forename: Marian
authors.initials: M
authors.lastname: Branny
authors.affiliation: Department of Cardiology, East Slovakia Institute for Cardiovascular Diseases, Kosice, Slovakia.
authors.forename: Martin
authors.initials: M
authors.lastname: Studenčan
authors.affiliation: Department of Cardiology, Second Medical School, Charles University, University Hospital Motol, Prague, Czech Republic.
authors.forename: David
authors.initials: D
authors.lastname: Zemánek
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D003324:Coronary Artery Disease / Q000097:blood / Q000188:drug therapy* / Q000601:surgery; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D005260:Female; D005464:Fluorobenzenes / Q000008:administration & dosage*; D005500:Follow-Up Studies; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D062645:Percutaneous Coronary Intervention; D011184:Postoperative Period; D011743:Pyrimidines / Q000008:administration & dosage*; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000008:administration & dosage*; D016896:Treatment Outcome; D019210:Troponin I / Q000097:blood* / Q000187:drug effects
chemical_list: D015415:Biomarkers; D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; D019210:Troponin I; D000068718:Rosuvastatin Calcium